This new formulation has the potential to favourably impact on the clinical daily management of HER2-positive early BC patients and represents an important opportunity for a less invasive, faster and safer drug administration with expected time-saving benefits and side-effects reduction, including catheter-associated discomfort, thrombosis and infection [[50], [51], [52], [53], [54]]. The gene discussed is ERBB2; the disease is infection.